MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development growth accelerates
Q3 FY2026 research & development of $32.05M rose 66.3% year over year, ahead of the +35.7% change in trailing-twelve-month research & development. Sequentially, it rose 3.4% from the prior quarter. Over 3 fiscal years it compounded at +54.7% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +66.3% holds above the trailing-twelve-month pace of +35.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 79.16M USD
- Year-over-year change
- +37.9%
- 3-year CAGR
- +54.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 79.16M | +37.9% |
| FY2024 | 2024-12-31 | 57.42M | +101.2% |
| FY2023 | 2023-12-31 | 28.53M | +33.4% |
| FY2022 | 2022-12-31 | 21.4M | — |
Research & Development vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +35.7% is the 2nd highest of 8, against a peer median of -10.0%.
- Over three fiscal years its annual growth of +54.7% compares with a peer median of -0.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $509.32M USD | +227.9% | +85.3% | — | |
| LTM Sep 2026 | €274.3M EUR | -10.0% | -9.3% | 22.7% | |
| LTM Sep 2026 | $179.67M USD | +7.9% | +15.5% | 64.0% | |
KLRAKailera Therapeutics, Inc. | FY2025 | $109.11M USD | — | — | — |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $101.27M USD | +35.7% | +54.7% | — |
| LTM Mar 2026 | $66.77M USD | -12.8% | -2.0% | 185483.3% | |
| LTM Mar 2026 | $48.2M USD | -55.0% | -0.4% | — | |
| LTM Mar 2026 | $32.2M USD | +26.3% | +14.1% | 10.2% | |
| LTM Mar 2026 | $5.77M USD | -21.5% | -38.7% | — | |
| Peer median (excluding MBX) | — | -10.0% | -0.4% | 43.3% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 248K |
| Gross Profit | 0 | 0 | 0 | (248K) |
| Gross Margin | — | — | — | — |
| Research & Development | 21.4M | 28.53M | 57.42M | 79.16M |
| Selling, General & Admin | 3.76M | 6.78M | 10.78M | 18.9M |
| Operating Expenses | 25.16M | 35.31M | 68.19M | 98.06M |
| Depreciation & Amortization | 56K | 157K | 244K | 248K |
| EBITDA | (25.71M) | (32.41M) | (61.68M) | (86.72M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (25.16M) | (35.31M) | (68.19M) | (98.06M) |
| Operating Margin | — | — | — | — |
| Interest Income | 372K | 2.75M | 6.27M | 11.08M |
| Interest Expense | 374K | 0 | 0 | 0 |
| Other Income / Expenses | (974K) | 2.75M | 6.27M | 11.08M |
| Income Before Tax | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.82) | (1.02) | (1.85) | (2.38) |
| EPS (Diluted) | (0.82) | (1.02) | (1.85) | (2.38) |
| Weighted Avg Shares | 31.85M | 31.85M | 33.39M | 36.51M |
| Weighted Avg Shares (Diluted) | 31.85M | 31.85M | 33.39M | 36.51M |
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.